All In Biotech

Drug Trial Radar · NCT05683418

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

241

Planned (sponsor's estimate)

Start

Feb 15, 2023

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Totus MedicinesIndustry
Sponsor type
Industry
First posted
Jan 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study enrollment criteria. The main questions it aims to answer are: 1. Phase 1a: what is the maximum tolerated dose and recommended dose for phase 2? 2. Phase 1a: how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day? 3. Phase 1b: how safe and effective is TOS-358 when given with standard of care medicines for HR+HER2- metastatic breast cancer (fulvestrant and CDK4/6i)

Conditions

  • HR+/HER2-negative Breast Cancer

Interventions

  • TOS-358Drug

    Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor

  • FulvestrantDrug

    Intramuscular SERD at standard doses

  • PalbociclibDrug

    CDK4/6 inhibitor at standard doses

  • RibociclibDrug

    CDK4/6 inhibitor at standard doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the rate of dose-limiting toxicities (DLTs)Time frame: First 21 days of treatment
  2. Incidence and severity of adverse events (AEs) and specific laboratory abnormalities graded according to NCI CTCAE v5Time frame: Start of treatment to 30 days after last dose

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Southern California Cancer Center

    Los Angeles, California · Recruiting

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Not yet recruiting

  • Florida Cancer Specialists & Research Institute

    St. Petersburg, Florida · Not yet recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • Maryland Oncology Hematology Cancer Specialists

    Calverton, Maryland · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Terminated

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Terminated

  • Compass Oncology West Cancer Center

    Tigard, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Terminated

  • Sarah Cannon Cancer Center

    Nashville, Tennessee · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Flower Mound

    Flower Mound, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Terminated

  • Blue Ridge Cancer Care

    Roanoke, Virginia · Recruiting

  • NEXT Oncology - Hospital Quironsalud Barcelona - PPDS

    Barcelona, Spain · Recruiting

  • START Barcelona HM Nou Delfos

    Barcelona, Spain · Recruiting

  • Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

    Barcelona, Spain · Recruiting

  • Hospital Clinico San Carlos

    Madrid, Spain · Recruiting

  • START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS

    Madrid, Spain · Terminated

  • START MADRID Hospital Universitario HM Sanchinarro - CIOCC

    Madrid, Spain · Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Spain · Terminated

  • NEXT Oncology - Hospital Quironsalud Madrid - PPDS

    Pozuelo de Alarcón, Spain · Terminated

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.